Literature DB >> 2861661

Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.

M F Beal, M F Mazurek, V T Tran, G Chattha, E D Bird, J B Martin.   

Abstract

Somatostatin receptor concentrations were measured in patients with Alzheimer's disease and controls. In the frontal cortex (Brodmann areas 6, 9, and 10) and temporal cortex (Brodmann area 21), the concentrations of somatostatin in receptors in the patients were reduced to approximately 50 percent of control values. A 40 percent reduction was seen in the hippocampus, while no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus. Scatchard analysis showed a reduction in receptor number rather than a change in affinity. Somatostatin-like immunoreactivity was significantly reduced in both the frontal and temporal cortex. Somatostatin-like immunoreactivity was linearly related to somatostatin-receptor binding in the cortices of Alzheimer's patients. These findings may reflect degeneration of postsynaptic neurons or cortical afferents in the patients' cerebral cortices. Alternatively, decreased somatostatin-like immunoreactivity in Alzheimer's disease might indicate increased release of somatostatin and down regulation of postsynaptic receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861661     DOI: 10.1126/science.2861661

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

1.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

2.  Somatostatin content and receptors in the cerebral cortex of depressed and control subjects.

Authors:  B G Charlton; A Leake; C Wright; A F Fairbairn; I G McKeith; J M Candy; I N Ferrier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

3.  Age-associated changes in hippocampal-dependent cognition in Diversity Outbred mice.

Authors:  Ming Teng Koh; Amy M Spiegel; Michela Gallagher
Journal:  Hippocampus       Date:  2014-06-11       Impact factor: 3.899

Review 4.  Somatostatin.

Authors:  S R Bloom; J M Polak
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

5.  Expression of five somatostatin receptor mRNAs in the human brain and pituitary.

Authors:  V S Thoss; J Pérez; A Probst; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 6.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

7.  Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers.

Authors:  Hansen Wang; Lisa D Muiznieks; Punam Ghosh; Declan Williams; Michael Solarski; Andrew Fang; Alejandro Ruiz-Riquelme; Régis Pomès; Joel C Watts; Avi Chakrabartty; Holger Wille; Simon Sharpe; Gerold Schmitt-Ulms
Journal:  Elife       Date:  2017-06-26       Impact factor: 8.140

8.  Effect of acute and chronic diisopropylfluorophosphate and atropine administration on somatostatin binding in the rat frontoparietal cortex and hippocampus.

Authors:  I A Alonso; J C Prieto; E Arilla
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease.

Authors:  G Stennis Watson; Laura D Baker; Brenna A Cholerton; Kristoffer W Rhoads; George R Merriam; Gerard D Schellenberg; Sanjay Asthana; Monique Cherrier; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity.

Authors:  Ujendra Kumar
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.